Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer Metastatic|Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: DRUG: Combination, Rogaratinib + palbociclib + fulvestrant
Sponsor: Fundacion CRIS de Investigación para Vencer el Cáncer
Collaborators: Bayer|Pfizer|Apices Soluciones S.L.